Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.53 |
| ▸ | HTT | P42858 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2961017 | 1.00 | MAPT (0.53) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL9533846 | 0.79 | RECQL (0.56) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL9533855 | 0.79 | RECQL (0.56) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL5480229 | 0.79 | BCHE (0.62) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL5477573 | 0.78 | MAPT (0.61) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL9530453 | 0.78 | RECQL (0.55) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL5946453 | 0.77 | MAPT (0.77) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL5478964 | 0.76 | RECQL (0.60) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL7364611 | 0.74 | ALDH1A1 (0.67) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL525132 | 0.74 | ALDH1A1 (0.67) | MAPTALDH1A1HTTGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772394-B2 | alkylating 3-[3-(dimethylamino)-1-oxo-2-propenyl]-phenyl]-acetamide with ethyl iodide in the presence of an alkali metal hydroxide or alkoxide in an aprotic solvent, condensing intermediate and 3-amino-4-cyanopyrazole in presence of water insoluble acid (edetic acid), ion exchange resin, water | CIPLA LIMITED (IN) | 2010-08-10 | — | — | US | claimed |
| US-20070191399-A1 | Zaleplon synthesis | CIPLA LIMITED (IN) | 2007-08-16 | — | — | US | claimed |
| WO-2005023813-A1 | ZALEPLON SYNTHESIS | CIPLA LIMITED (IN) | 2005-03-17 | — | — | WO | claimed |
| US-7772394-B2 | alkylating 3-[3-(dimethylamino)-1-oxo-2-propenyl]-phenyl]-acetamide with ethyl iodide in the presence of an alkali metal hydroxide or alkoxide in an aprotic solvent, condensing intermediate and 3-amino-4-cyanopyrazole in presence of water insoluble acid (edetic acid), ion exchange resin, water | CIPLA LIMITED (IN) | 2010-08-10 | — | — | US | disclosed |
| US-7772394-B2 | alkylating 3-[3-(dimethylamino)-1-oxo-2-propenyl]-phenyl]-acetamide with ethyl iodide in the presence of an alkali metal hydroxide or alkoxide in an aprotic solvent, condensing intermediate and 3-amino-4-cyanopyrazole in presence of water insoluble acid (edetic acid), ion exchange resin, water | CIPLA LIMITED (IN) | 2010-08-10 | — | — | US | disclosed |
| US-20070191399-A1 | Zaleplon synthesis | CIPLA LIMITED (IN) | 2007-08-16 | — | — | US | disclosed |
| US-20070191399-A1 | Zaleplon synthesis | CIPLA LIMITED (IN) | 2007-08-16 | — | — | US | disclosed |
| WO-2005023813-A1 | ZALEPLON SYNTHESIS | CIPLA LIMITED (IN) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023813-A1 | ZALEPLON SYNTHESIS | CIPLA LIMITED (IN) | 2005-03-17 | — | — | WO | disclosed |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | P2RX3, P2RX2, P2RX5 | MAPT 1996/4885ALDH1A1 1913/4885HTT 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.